At first glance, it appears to be an ordinary hygiene product. However, the innovative MenstruAI , developed in Switzerland, has the potential to revolutionize women’s health. The name combines “menstruation” and “AI” (artificial intelligence), indicating its functionality: an analysis of menstrual blood using a reactive strip, with results that can be seen with the naked eye or via a mobile app powered by AI.
Created by a team at the Swiss Federal Institute of Technology in Zurich (ETH Zurich) , led by Professor Dimos Poulikakos , this device aims to detect specific biomarkers for serious illnesses like endometriosis and certain gynecological cancers from the onset of the menstrual cycle.
This concept may seem ambitious, but it is grounded in scientific reality: menstrual blood is a treasure trove of medical information.
MenstruAI: What is This New Screening Device?
Endometriosis and Ovarian Cancer: Invisible Illnesses, Now Made Visible?
One clear motivation behind this project is to shorten the often lengthy diagnostic timeframe for debilitating conditions. For instance, in France, nearly 2 million women suffer from endometriosis , according to Inserm . Unfortunately, diagnosis typically occurs an average of seven years after initial symptoms appear. Ovarian cancer, though less common, is particularly deadly, with approximately 5,200 new cases diagnosed annually, leading to around 3,500 deaths, as reported by Public Health France .
The MenstruAI device targets three proteins found in menstrual blood: CRP , CA-125 , and CEA . The device features a reactive strip that changes color in response to these biomarkers, while a mobile app allows users to analyze results within minutes.
Menstrual Blood: A Waste Turned Ally
Historically, minimal research has focused on the medical potential of menstrual blood . Yet, it represents a non-invasive alternative to traditional blood tests, offering comparable data on key proteins.
For example, the CRP level indicates an inflammatory state, which is common in endometriosis. The CA-125 protein is recognized as a tumor marker for ovarian cancer. Meanwhile, CEA is frequently monitored in patients with certain gynecological or digestive cancers.
Revolution in Menstrual Health: The MenstruAI Movement
A Technological Leap, yet Not (Yet) a Diagnostic Test
It is important to note that MenstruAI is not a diagnostic test per se; it functions as an early warning device, akin to a thermometer indicating when one should seek medical attention. Confirmatory medical exams are still necessary for an official diagnosis.
Clinical trials are currently ongoing to scientifically validate this new tool’s reliability. Early data appears promising, and the Swiss researchers hope to introduce this product to the market within the next few years.
Towards the Democratization of Gynecological Screening
MenstruAI could significantly change the landscape in areas with limited access to healthcare. A sanitary pad capable of detecting serious illnesses—usable at home and without medical equipment—could become a vital resource for millions of women.
This innovation also seeks to eliminate the taboo surrounding menstruation and place female health at the forefront of medical advancement. By valuing menstrual blood as a health indicator, MenstruAI embraces a vision of preventive medicine that is more accessible, inclusive, and equitable.
Did You Know?
The blood released during menstruation contains cells that can repair tissues in the body. Researchers are exploring this potential for developing new treatments for diseases like endometriosis or chronic pain .